Haddad Ghazal, Maslove David M, Mbuagbaw Lawrence, Belley-Côté Emilie P, Rochwerg Bram
Department of Medicine, McMaster University, Hamilton, ON, Canada.
Department of Critical Care Medicine, Queen's University, Kingston, ON, Canada.
Crit Care Explor. 2025 Jan 31;7(2):e1210. doi: 10.1097/CCE.0000000000001210. eCollection 2025 Feb 1.
While corticosteroid administration in septic shock has been shown to result in faster shock reversal and lower short-term mortality, the role of corticosteroids in the management of cardiogenic shock (CS) remains unexplored.
Determine the impact of corticosteroid administration on 90-day mortality (primary outcome) in patients admitted to a critical care unit with CS.
DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, we used the critical care database of Medical Information Mart for Intensive Care-IV, and included all adult patients diagnosed with CS excluding repeated admissions, patients with adrenal insufficiency, those receiving baseline corticosteroids, and those requiring extracorporeal life support. We considered exposure based on receiving systemic corticosteroids from 6 hours before to 24 hours post-critical care admission.
We calculated Cox proportional hazards using multivariate analysis for 90-day mortality (primary outcome). We also explored the association of corticosteroid use with hospital length of stay, ventilator-free days (VFDs), vasopressor-free days, ventilator-associated pneumonia, central-line-associated bloodstream infections, and hyperglycemia.
We included 2000 eligible patients, with 143 (7.2%) receiving systemic corticosteroids. Corticosteroid-treated patients were younger (67.7 vs. 71.2 yr; p = 0.006), had higher Sequential Organ Failure Assessment scores at baseline (9.4 vs. 7.8; p < 0.001), and more often required vasopressors (78% vs. 63%; p < 0.001), and invasive mechanical ventilation (73% vs. 45%; p < 0.001). Corticosteroid use was associated with increased 90-day mortality in multivariate analysis (hazard ratio, 1.60; 95% CI, 1.25-2.05) and fewer VFDs (2.8 d fewer; 95% CI, 0.35-5.26) with no effect on other secondary outcomes.
Use of corticosteroids may be associated with increased mortality and a reduction in VFDs in patients admitted to critical care with CS. These findings suggesting potential harm of corticosteroids in CS might reflect unmeasured confounding and require corroboration through additional observational studies and ultimately randomized clinical trials.
虽然已证明在感染性休克中使用皮质类固醇可使休克逆转更快且短期死亡率更低,但皮质类固醇在心源性休克(CS)管理中的作用仍未得到探索。
确定在入住重症监护病房的CS患者中,使用皮质类固醇对90天死亡率(主要结局)的影响。
设计、背景和参与者:在这项回顾性队列研究中,我们使用了重症监护医学信息集市-IV的重症监护数据库,纳入了所有诊断为CS的成年患者,排除重复入院患者、肾上腺功能不全患者、接受基线皮质类固醇治疗的患者以及需要体外生命支持的患者。我们根据从重症监护入院前6小时至入院后24小时接受全身性皮质类固醇治疗来定义暴露。
我们使用多变量分析计算90天死亡率(主要结局)的Cox比例风险。我们还探讨了使用皮质类固醇与住院时间、无呼吸机天数(VFD)、无血管升压药天数、呼吸机相关性肺炎、中心静脉导管相关血流感染和高血糖之间的关联。
我们纳入了2000例符合条件的患者,其中143例(7.2%)接受了全身性皮质类固醇治疗。接受皮质类固醇治疗的患者更年轻(67.7岁对71.2岁;p = 0.006),基线时序贯器官衰竭评估评分更高(9.4对7.8;p < 0.001),更常需要血管升压药(78%对63%;p < 0.001)和有创机械通气(73%对45%;p < 0.001)。在多变量分析中,使用皮质类固醇与90天死亡率增加相关(风险比,1.60;95%置信区间,1.25 - 2.05),且VFD减少(减少2.8天;95%置信区间,0.35 - 5.26),对其他次要结局无影响。
在入住重症监护病房的CS患者中,使用皮质类固醇可能与死亡率增加和VFD减少有关。这些表明皮质类固醇在CS中可能有害的发现可能反映了未测量的混杂因素,需要通过额外的观察性研究并最终通过随机临床试验来证实。